Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1993 1
1994 2
1996 1
1999 2
2000 1
2001 1
2002 1
2003 5
2004 2
2005 5
2006 4
2007 6
2008 4
2009 7
2010 6
2011 6
2012 3
2013 8
2014 5
2015 4
2016 4
2017 6
2018 2
2019 4
2020 3
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

80 results
Results by year
Filters applied: . Clear all
Page 1
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies.
Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G. Hogberg T, et al. Among authors: tognon g. Eur J Cancer. 2010 Sep;46(13):2422-31. doi: 10.1016/j.ejca.2010.06.002. Epub 2010 Jul 7. Eur J Cancer. 2010. PMID: 20619634 Free PMC article. Clinical Trial.
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
Lorusso D, Bologna A, Cecere SC, De Matteis E, Scandurra G, Zamagni C, Arcangeli V, Artioli F, Bella M, Blanco G, Cardalesi C, Casartelli C, De Vivo R, Di Napoli M, Gisone EB, Lauria R, Lissoni AA, Loizzi V, Maccaroni E, Mangili G, Marchetti C, Martella F, Naglieri E, Parolin V, Ricciardi G, Ronzino G, Salutari V, Scarfone G, Secondino S, Spagnoletti I, Tasca G, Tognon G, Guarneri V. Lorusso D, et al. Among authors: tognon g. Support Care Cancer. 2020 May;28(5):2435-2442. doi: 10.1007/s00520-020-05320-4. Epub 2020 Feb 11. Support Care Cancer. 2020. PMID: 32048043
Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study.
Calura E, Ciciani M, Sambugaro A, Paracchini L, Benvenuto G, Milite S, Martini P, Beltrame L, Zane F, Fruscio R, Marchette MD, Borella F, Tognon G, Ravaggi A, Katsaros D, Bignotti E, Odicino F, D'Incalci M, Marchini S, Romualdi C. Calura E, et al. Among authors: tognon g. Cells. 2019 Dec 1;8(12):1554. doi: 10.3390/cells8121554. Cells. 2019. PMID: 31805750 Free PMC article.
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
Benvenuto G, Todeschini P, Paracchini L, Calura E, Fruscio R, Romani C, Beltrame L, Martini P, Ravaggi A, Ceppi L, Sales G, Donati F, Perego P, Zanotti L, Ballabio S, Grassi T, Delle Marchette M, Tognon G, Sartori E, Adorni M, Odicino F, D'Incalci M, Bignotti E, Romualdi C, Marchini S. Benvenuto G, et al. Among authors: tognon g. Int J Cancer. 2020 Jul 15;147(2):565-574. doi: 10.1002/ijc.32935. Epub 2020 Mar 13. Int J Cancer. 2020. PMID: 32096871
Unique features of the mode of action of ET-743.
D'Incalci M, Erba E, Damia G, Galliera E, Carrassa L, Marchini S, Mantovani R, Tognon G, Fruscio R, Jimeno J, Faircloth GT. D'Incalci M, et al. Among authors: tognon g. Oncologist. 2002;7(3):210-6. doi: 10.1634/theoncologist.7-3-210. Oncologist. 2002. PMID: 12065793 Free article. Review.
Prognostic factors in early-stage ovarian cancer.
Tognon G, Carnazza M, Ragnoli M, Calza S, Ferrari F, Gambino A, Zizioli V, Notaro S, Sostegni B, Sartori E. Tognon G, et al. Ecancermedicalscience. 2013 Jun 13;7:325. doi: 10.3332/ecancer.2013.325. Print 2013. Ecancermedicalscience. 2013. PMID: 23781280 Free PMC article.
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
Tassi RA, Gambino A, Ardighieri L, Bignotti E, Todeschini P, Romani C, Zanotti L, Bugatti M, Borella F, Katsaros D, Tognon G, Sartori E, Odicino F, Romualdi C, Ravaggi A. Tassi RA, et al. Among authors: tognon g. Br J Cancer. 2019 Oct;121(7):584-592. doi: 10.1038/s41416-019-0553-z. Epub 2019 Aug 22. Br J Cancer. 2019. PMID: 31434988 Free PMC article.
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
Colombo N, Zaccarelli E, Baldoni A, Frezzini S, Scambia G, Palluzzi E, Tognon G, Lissoni AA, Rubino D, Ferrero A, Farina G, Negri E, Pesenti Gritti A, Galli F, Biagioli E, Rulli E, Poli D, Gerardi C, Torri V, Fossati R, D'Incalci M. Colombo N, et al. Among authors: tognon g. Br J Cancer. 2019 Oct;121(9):744-750. doi: 10.1038/s41416-019-0584-5. Epub 2019 Sep 20. Br J Cancer. 2019. PMID: 31537908 Free PMC article. Clinical Trial.
80 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page